The Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) plays a key role in apoptosis and decreases phosphorylation of Akt. Apoptosis of cardiomyocytes is thought to contribute to the increased area of acute myocardial infarction (AMI), and Akt activation exerts a powerful cardioprotective effect after ischemia. Thus, a therapeutic strategy designed to inhibit expression of SHP-1 would be beneficial in AMI. Here we report that siRNA targeting SHP-1 reduced infarct size in a rat model of AMI. Upon injection into the ischemic left ventricular wall, the vector-based siRNA significantly suppressed the increase in the SHP-1 mRNA and the SHP-1 protein levels. The siRNA vector also significantly reduced the SHP-1 that bound to Fas-R. The SHP-1 siRNA vector increased phospho-Akt and reduced DNA fragmentation and caspase activity compared with the scramble siRNA vector. Finally, the area of myocardial infarction was significantly smaller with the SHP-1 siRNA vector than with the scramble siRNA vector at 2 days after LCA ligation. In conclusion, SHP-1 in the heart increased from the early stage of AMI, and this increase was thought to contribute to the increased area of myocardial infarction. Suppression of SHP-1 with the SHP-1 siRNA vector markedly reduced the infarct size in AMI.
. SHP-1 also has a key role in apoptosis in many cells (11) (12) (13) , and death receptors such as TNFR1 and FAS-R bind SHP-1 and block anti-apoptotic signals in neutrophils (14) . In addition, SHP-1 decreases phosphorylation of Akt, a process dependent on PI3K activity (15) . Akt activation exerts a powerful cardioprotective effect after transient ischemia (16) . Accordingly, we hypothesized that the suppression of SHP-1 in the myocardium would reduce the apoptosis of cardiomyocytes and activate Akt and thereby protect the myocardium from infarct in vivo. However, the relation of SHP-1 to AMI has never been examined. In the present study, we examined the effects of SHP-1 on infarct size in AMI by using small interfering RNA (siRNA) targeting the SHP-1 gene.
MATERIALS AND METHODS

siRNA Expression vector
The siRNA expression vectors (pRNA-U6.1/Neo) were purchased from GenScript Corporation (Piscataway, NJ). The sequences were the following:
rat SHP-1 siRNA, GGATCCCGTGGATCCGAATATGAGTCACCTTGATATCCGGGTGACTCATATTCGGAT CCATTTTTTCCAAAAGCTT; and scramble siRNA, GGATCCCGATAACATATTCGGACCGTGCTTGATATCCGGCACGGTCCGAATATGTTA TCTTTTTTCCAAAAGCTT.
Animal treatment
Male Wistar rats (250-300 g) were subjected to left coronary artery ligation as described previously (17) . We confirmed ischemia of the regional myocardia by monitoring the change of the ST segment level on the electrocardiogram and by observing the change in the color of the myocardia. Rats were assigned in a random blind fashion to one of four groups, as follows: (a) SHP-1 siRNA vector administration, (b) scramble siRNA vector administration, (c) saline administration, or (d) sham-operated. We administered each vector (total 100 μg) by direct injection to the left ventricular wall in three different sites (from base to apex) immediately after the coronary artery ligation was performed. All experiments were also performed blindly with respect to the treatment.
Measurement of myocardial infarct size
After 2 days of coronary artery ligation, the rats were killed and their hearts were removed. The ascending aorta was canulated with a 22-gauge catheter, and 1% Evans blue was perfused into the aorta and coronary arteries to delineate the area at risk. The heart was excised and then the heart was cut transversely into four sections from the apex to the base. The slices were then incubated for 20 min with 1% triphenyl tetrazolium chloride (TTC) solution in 0.2 mol/L Tris buffer (pH 8.0) at 25°C. After TTC staining, the infarct area appears pallid, whereas the viable myocardium appears red. The each slice was photographed then analyzed using the NIH image program. The myocardial infarct size was expressed as the percentage of the infarct area/the area at risk as described previously (17) .
Northern blotting
The rat SHP-1 mRNA was determined by Northern blot analysis using the DIG detection system (Roche Applied Science, Japan) after 1 and 2 days of coronary artery ligation. The rat cDNA for SHP-1 was produced by RT-PCR according to the rat sequence (ACCESSION U77038). The sense and anti-sense primers used for RT-PCR were as follows: sense, 5′-GCACCATCATCCACCTCAAGT-3′; anti-sense, 5′-GTTCTCCTGCCAAGCCATCTG-3; size, 758 bp. The PCR fragment was gel-purified using a QIAEX II gel extraction kit and cloned into the TOPO TA expression plasmid (Invitrogen, Carlsbad, CA). The recombinant plasmid was linearized and used as a cDNA template. The RNA probe was produced using DIG RNA labeling kit (Roche Applied Science, Tokyo, Japan).
Western blotting
After 1 and 2 days of coronary artery ligation, the whole myocardial tissue was washed and frozen in liquid nitrogen. The tissue was homogenated with five volumes of homogenization buffer (RIPA), after which the supernatants were fractionated on SDS-PAGE and blotted to a Hybond-P membrane. The membranes were blocked with 5% nonfat dry milk in 1 ´ TBS containing 0.05% Tween 20 and incubated with the antibodies against SHP-1 (Santa Cruz Biotechnology, Santa Cruz, CA), SHP-2 (Santa Cruz Biotechnology), Akt (Upstate, Lake Placid, NY), or phopho Akt (Cell Signaling Technology, Beverly, MA). Detection was performed with secondary HRP-conjugated antibodies and the ECL detection system.
Immunoprecipitation and immunoblotting
The tissue homogenates were clarified by centrifugation. For immunoprecipitation, the supernatants were shaken with antisera to Fas-R (Santa Cruz Biotechnology) for 2 h at 4°C, after which 50 μl of a slurry of protein A/G-plus-agarose (Santa Cruz Biotechnology) was added. Incubation was continued overnight at 4°C. The immunoprecipitated proteins were fractionated on 7.5% SDS-PAGE and blotted to a Hybond-P membrane. The membranes were also blocked and incubated with the antibody against SHP-1. Detection was performed with secondary HRP-conjugated antibodies (Chemicon, Temecula, CA) and the ECL detection system.
Analyses of apoptosis
After 1 and 2 days of coronary artery ligation, total genomic DNA was isolated from the whole heart of rats with a DNA isolation kit (Biotex, Friendswood, TX) according to the manufacturer's instructions, and the DNA was analyzed by electrophoresis on a 1.5% TraviGel 500 gel. Caspase-3 activity was determined as described previously (17) . Briefly, the hearts of rats were frozen in liquid nitrogen and were homogenized in lysis buffer, and the 50 μl homogenate was mixed with 50 μl reaction buffer (10 mM PIPES, pH 7.4; 2 mM EDTA; and 0.1% CHAPS) containing 200 μM Z-DEVD-AMC substrate. Substrate cleavage to release free AMC (340ex nm, 460em nm) was monitored at room temperature. Fluorescent units were converted to pmol AMC using a standard curve generated with free AMC.
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Echocardiography LV dimension and function were assessed with echocardiography. After 2 days of coronary artery ligation, the animals were anesthetized with pentobarbital sodium (50 mg/kg IP) and images were recorded using a 10-12 MHz phased-array transducer (LOGIQ 400 PRO, GE Medical Systems, Milwaukee, WI). End-diastolic and end-systolic dimensions of the left ventricle (LVDd and LVSd, respectively) were derived from two-dimensionally targeted M-mode tracings obtained along the short-axis view of the left ventricle at the papillary muscle level and were obtained by averaging at least three consecutive cardiac cycles. All measurements were evaluated by two cardiologists in a blind fashion according to the American Society for Echocardiology.
Statistical analysis
All values are presented as mean ± SEM. Statistical significance was evaluated using the unpaired Student's t test for comparison between two means. Comparisons among three or more groups were made using the one-way ANOVA followed by Dunnett's modified test. Differences were considered to be statistically significant at a P value of <0.05.
RESULTS
The amount of SHP-1 mRNA increased in the myocardium injected with the SHP-1 siRNA vector and the scramble siRNA vector, compared with the amount in sham-operated rats (Fig.  1A) . Throughout the experiment, the SHP-1 siRNA vector treatment significantly reduced SHP-1 mRNA (Fig. 1B) . The amount of SHP-1 mRNA in muscles was not significantly different between treatment with the scramble siRNA and treatment with saline throughout the experiment (data not shown). Western blot analysis also showed that SHP-1 was higher in both the myocardium injected with the SHP-1 siRNA vector and that injected with the scramble siRNA vector, compared with the amount in sham-operated rats (Fig. 2) . Throughout the experiment, the SHP-1 siRNA vector treatment reduced SHP-1 (Fig. 2) . In contrast, the amount of SHP-2 did not differ between the rats treated with the SHP-1 siRNA vector and those treated with the scramble siRNA vector throughout the experiment (Fig. 2) . Since SHP-1 decreases the phosphorylation of Akt and Akt activation exerts a powerful cardioprotective effect after ischemia, we examined the phosphorylation of Akt in the myocardium injected with the SHP-1 siRNA vector. Throughout the experiment, the SHP-1 siRNA vector induced a greater level of phosphorylation of Akt than the scramble siRNA vector (Fig. 2) . Densitometric quantification of the phosphorylation of Akt/Akt ratio was significantly higher in rats receiving the SHP-1 siRNA vector than in those receiving the scramble siRNA vector (1 day, 0.96±0.04 vs. 0.67±0.04; 2 days, 0.61±0.04 vs. 0.47±0.03; SHP-1 siRNA vs. scramble siRNA, respectively, P<0.01 at 1 day and P<0.05 at 2 days; n=6 at each time and each group). Fas-R was immunoprecipitated from the hearts to determine the association of SHP-1 with Fas-R. The SHP-1 siRNA vector treatment significantly reduced the amount of SHP-1 that bound to Fas-R (Fig. 3) . Because SHP-1 is required for Fas-mediated cytotoxic signaling that causes intracellular acidification and apoptosis, we proposed that the reduction in SHP-1 recruitment has an anti-apoptotic effect. Apoptosis was confirmed by DNA fragmentation using 1.5% TraviGel 500 gel electrophoresis (Fig. 4A) . The internucleosomic fragmentation in cardiomyocytes was prevented by the treatment of the SHP-1 siRNA vector (Fig. 4A) . A caspase activity assay in the myocardium also showed that the caspase activity was significantly lower in rats receiving the SHP-1 siRNA vector than in those receiving the scramble siRNA vector (Fig. 4B) . The SHP-1 siRNA vector markedly reduced the area of myocardial infarction at 2 days after coronary artery ligation (Fig. 5A, B) , whereas no difference was observed between rats treated with the scramble siRNA vector and those treated with saline (data not shown). To examine whether or not the SHP-1 siRNA vector improved cardiac function, we measured LV end-diastolic dimension (LVDd), LV end-systolic dimension (LVDs), and fractional shortening (FS) by echocardiography. At 2 days after the LCA ligation, the LVDd was significantly lower and the FS was significantly higher in the rats treated with SHP-1 siRNA vector than in those treated with the scramble siRNA vector (Fig. 6A, B) .
DISCUSSION
Hypoxia not only causes necrosis of the myocardium but also activates the suicide program of neonatal cardiac myocytes (18) . It is known that TUNEL-positive staining of cardiomyocytes is increased in ischemia/reperfusion injury (6, 19) . Given that apoptosis is the major independent form of cardiomyocyte cell death in acute myocardial infarction (AMI), with necrosis running a close second (6), it is possible that a reduction in the apoptosis of cardiomyocytes would reduce the area of myocardial infarction. And in fact, administration of ZVAD-fmk, a caspase inhibitor, has been shown to reduce both the size of the myocardial infarct as assessed by TTC staining, and the number of TUNEL-positive cardiomyocytes in rats that underwent 30 min coronary occlusion and 24 h reperfusion (20) . These results suggest that the attenuation of cardiomyocyte apoptosis reduces infarct size in vivo. The Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1), a cytoplasmic protein tyrosine phosphatase, plays a negative regulatory role in signal transduction pathways by dephosphorylation of the receptors to which it binds (7-10). SHP-1 also has a key role in apoptosis in many cells (11) (12) (13) , and death receptors such as TNFR1 and FAS-R bind SHP-1 and block anti-apoptotic signals in neutrophils (14) . Thus, SHP-1 is thought to play an important role in apoptosis and/or the blocking of survival factors. It is known that SHP-1 protein levels are up-regulated following cerebral ischemia, which may contribute to increased cerebral infarction (21) . However, no studies no have examined whether SHP-1 levels are increased in AMI. In the present study, we have shown for the first time that SHP-1 protein levels are also up-regulated in AMI. We thus hypothesized that in AMI, the increase in SHP-1 might stimulate apoptosis of cardiomyocytes, which in part contributes to increased infarct size. Transfection of mammalian cells with synthetic small interfering RNAs (siRNA) specifically suppresses the expression of endogenous and heterologous genes by RNA interference (RNAi) in cell culture (22) . This mechanism is highly gene specific and turns off the expression of the target protein (23, 24) . Some studies have developed vectors or viruses to produce stable expression of siRNA in cells (25) . The in vivo regulation of various genes by RNAi has been achieved using these vectors or viruses (26) or by using a high-pressure technique (27, 28) . In the present study, we used a vector-based siRNA targeting SHP-1, which could achieve a stable expression of siRNA, to reduce SHP-1. The myocardium injected with the SHP-1 siRNA vector showed a significant decrease in SHP-1 mRNA as early as 1 day after injection and continuing until 2 days. Successful transfection also resulted in a reduction in SHP-1 protein expression in the myocardium injected with the SHP-1 siRNA vector. The success of the transfection may have been partly due to the vector used in the present study. In addition, in skeletal muscle, the transfection efficiency of intramuscular gene transfer is augmented from fivefold to sevenfold when the injected muscle is ischemic (29) . In the present study, association of SHP-1 with Fas-R was also suppressed with SHP-1 siRNA vector. SHP-1 is activated in the Fas receptor-mediated signaling in hematopoietic cells (30) . In addition, SHP-1 is required for the Fas-mediated cytotoxic signaling that causes intracellular acidification and apoptosis in breast adenocarcinoma cells (13) , and recruitment of SHP-1 to Fas-R blocks anti-apoptotic signals in neutrophils (14) . Thus, reduced SHP-1 recruitment to Fas-R may have had an anti-apoptotic effect on cardiomyocytes in the present study. In fact, Fas is known to induce apoptosis in cardiomyocytes, possibly due to stimulation of Fas-R (3, 4) , and Fas is a critical mediator of acute myocardial infarction (AMI) due to ischemia-reperfusion in vivo (5) . In the present study, the internucleosomic fragmentation in the heart was prevented by treatment with the SHP-1 siRNA vector. The caspase-3 activity in the heart was also lower in the rats receiving the SHP-1 siRNA vector than in those receiving the scramble siRNA vector until 2 days after the vector injection. Caspase-3 has been reported to be involved in apoptotic cell death in ischemic rat hearts (31) . Thus, these findings indicate that apoptosis in the ischemic rat heart is reduced by SHP-1 siRNA vector. Akt activation exerts a cardioprotective effect after ischemia that probably reflects its ability to both inhibit cardiomyocyte death and improve the function of surviving cardiomyocytes (16) . Transplantation of mesenchymal stem cells overexpressing Akt into the ischemic rat myocardium can repair infarcted myocardium, prevent remodeling, and nearly normalize cardiac performance (32) . In T lymphocytes, expression of SHP-1 has been shown to decrease the phosphatidylinositol 3-kinase (PI3K) enzyme activity and phosphorylation of Akt, a process dependent on PI3K activity (15) . These findings suggest that PI3K signaling, which has been implicated in cell proliferation, apoptosis, cytoskeletal reorganization and many other biological activities, can be regulated by SHP-1 in T lymphocytes. In the present study, the SHP-1 siRNA vector significantly increased phosphorylation of Akt throughout the experiment. These results indicate the presence of a functional interaction between PI3K and SHP-1 and suggest that PI3K signaling can also be regulated by SHP-1 in cardiomyocytes. In the present study, treatment with the SHP-1 siRNA vector suppressed the increase in SHP-1 in myocardial tissue, which was thought to reduce the apoptosis of cardiomyocytes and activate Akt. These effects may have contributed to the reduction of the area of myocardial infarction. However, in the present study, we cannot completely rule out the possibility that the reduction of infarct size by SHP-1 siRNA vector might have been partly due to the reduction of necrosis. In our recent study (17) , when the soluble TNF receptor 1 (sTNFR1) was injected into the myocardium immediately after the coronary artery ligation, the sTNFR1 plasmid had significantly reduced the apoptosis of cardiomyocytes and thereby reduced the area of myocardial infarction at 2 days after coronary artery ligation. TNF-α is known to inhibit the endothelial cell proliferative response through SHP-1 activation (33, 34) . Thus, in these previous findings, it is possible that sTNFR1, which is an antagonist of TNF-α, might have reduced the infarct size through SHP-1 inactivation. In conclusion, the present study showed, for the first time, the potential therapeutic value of the anti-SHP-1 therapy in the treatment of AMI. However, our study was limited to the period comprising only 2 days after the AMI. Therefore, in order to elucidate what the possible long-term benefit of anti-SHP-1 therapies of this type offer in the clinical arena, further longer-term studies are needed.
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We thank Yoshikazu Watanabe for his expert technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan. MM, DNA/Hind III fragmentation marker. B) The caspase activity in the myocardium was significantly lower in rats receiving the SHP-1 siRNA vector than in those receiving the scramble siRNA vector. Fluorescent units were expressed as pmol AMC/mim/μg prot. using a standard curve generated with free AMC and are expressed as mean ± SEM and (n=6 in each group). 
